Trial Profile
Clinical Trials Insight: 700044143
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 07 May 2009
Price :
$35
*
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 29 Apr 2009 Regulary approval has not been granted for the confirmatory trial in India (see 700032156) by the Directorate General of Health Services -Office of Drugs Controller General (India). DCGI requested concurrent enrolment of patients in this trial in the USA.
- 16 Oct 2008 Neopharm has signed a Cooperative Research and Development Agreement with the National Institute of Neurological Diseases and Stroke (NINDS), for research on a therapeutic agent for untreatable brain diseases in humans